uuid:229a4dc0-3419-472d-82c7-ba0f4852e335
xmp.did:BECB8E6CD501E0118139ABDD0BD95C31
adobe:docid:indd:55b2be19-d352-11de-a31b-ffe24ab5dd96
proof:pdf
xmp.iid:BDCB8E6CD501E0118139ABDD0BD95C31
xmp.did:FC05677AD6FEDF11B6BEB0C1DC3146AA
adobe:docid:indd:55b2be19-d352-11de-a31b-ffe24ab5dd96
default
saved
xmp.iid:DF4F1135F500DF1183D4C400F4FDAB2A
2010-01-14T12:11:40+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:E04F1135F500DF1183D4C400F4FDAB2A
2010-01-14T12:11:40+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:E14F1135F500DF1183D4C400F4FDAB2A
2010-01-14T12:57:47+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:E24F1135F500DF1183D4C400F4FDAB2A
2010-01-14T12:57:47+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:E34F1135F500DF1183D4C400F4FDAB2A
2010-01-14T13:05:54+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:E44F1135F500DF1183D4C400F4FDAB2A
2010-01-14T13:05:54+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:E54F1135F500DF1183D4C400F4FDAB2A
2010-01-14T13:06:32+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:E64F1135F500DF1183D4C400F4FDAB2A
2010-01-14T13:06:32+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:8B8F7935800ADF1196F4F0D3B5D1C75F
2010-01-26T15:39:21+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:EB908C55810ADF119871DD04D56AB754
2010-01-26T15:47:24+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:A7846867300FDF11BF5AA4F055A5AD9D
2010-02-01T14:50:41+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:B057E256CA0FDF119599DE52A871FFD0
2010-02-02T09:12:35+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:3825F28ACA0FDF119EBECC396F3E9DAD
2010-02-02T09:14:03+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:3925F28ACA0FDF119EBECC396F3E9DAD
2010-02-02T09:14:03+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:3A25F28ACA0FDF119EBECC396F3E9DAD
2010-02-02T09:15:25+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:3B25F28ACA0FDF119EBECC396F3E9DAD
2010-02-02T09:15:25+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:750D6B85D60FDF1188BCB36B58452661
2010-02-02T10:39:48+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:31194067DE0FDF11A5B2A403972F4363
2010-02-02T11:36:13+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:07ECB50BEE0FDF11BBB4F6BC3B9209ED
2010-02-02T13:28:11+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AD4FC578CB10DF118A8CA43869F3300B
2010-02-03T16:25:54+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:AE4FC578CB10DF118A8CA43869F3300B
2010-02-03T16:25:54+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:E17C070C2C12DF11B142D80DAF079995
2010-02-05T11:11:41+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:9FE1915B7B14DF11A14BB0E9A56DDE1E
2010-02-08T08:29:51+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:867F6D139614DF11848FA3FFF101FBD9
2010-02-08T11:41:04+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:897F6D139614DF11848FA3FFF101FBD9
2010-02-08T12:15:11+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:32753A1AB714DF118E28FDBAA5305E60
2010-02-08T15:37:29+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:176951A1BB17DF118887886E4ABEDC0E
2010-02-12T13:23+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:CF46D29CBB1BDF11B4B8FDDE6A3F4A4C
2010-02-17T14:00:48+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:A3827179AE38DF1189E6F2A4962AD137
2010-03-26T10:06:25+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:3477E364B243DF1186869D4BEEF890CA
2010-04-09T10:55:53+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AD3170A1C343DF11BE778C82F63CB51F
2010-04-09T12:48:45+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AE3170A1C343DF11BE778C82F63CB51F
2010-04-09T15:13:08+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:6ECB6C039247DF1195BFCCF10E897A16
2010-04-14T08:50:29+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:12FCE54E724CDF1199E8951AD8227FCF
2010-04-20T14:12:15+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AF3853F2DF58DF11A4F6F892A2F259B1
2010-05-06T12:17:44+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:0DFFBACC0359DF11A4F6F892A2F259B1
2010-05-06T13:37:49+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:CF57CA045462DF11B6D2C7DCD6C7E964
2010-05-18T10:04:44+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:D057CA045462DF11B6D2C7DCD6C7E964
2010-05-18T11:13:41+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FACCD3D48062DF11B59BA25A0A8354F6
2010-05-18T15:25:31+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FBCCD3D48062DF11B59BA25A0A8354F6
2010-05-18T15:26:18+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FCCCD3D48062DF11B59BA25A0A8354F6
2010-05-18T15:26:23+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:88D17199AA7ADF11BCBDBB26D015DE34
2010-06-18T09:45:10+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:918620765683DF11BC59B35A780499F7
2010-06-29T13:01:10+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:DDA394163E88DF119F88D8B0E8A3931B
2010-07-05T16:03:29+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:6F485926118FDF11837EA4CEF60DBE4A
2010-07-14T08:32:18+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:A8A10BA7AF90DF11B12C9778406FCB23
2010-07-16T11:10:26+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AC8CD32B9094DF11895AA966BA2EADDB
2010-07-21T08:21:17+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:AF8CD32B9094DF11895AA966BA2EADDB
2010-07-21T08:36:03+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:D0C753EAFEBEDF11BFC0D36D35EC0202
2010-09-13T08:19:50+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:D1C753EAFEBEDF11BFC0D36D35EC0202
2010-09-13T08:19:50+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:566B6F5D37BFDF119FFF87DEABBE45F2
2010-09-13T15:03:55+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:596B6F5D37BFDF119FFF87DEABBE45F2
2010-09-13T16:12:18+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:5A6B6F5D37BFDF119FFF87DEABBE45F2
2010-09-13T16:16:04+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:25E0390ADABFDF11AB1DF20C369C5409
2010-09-14T10:32:04+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:26E0390ADABFDF11AB1DF20C369C5409
2010-09-14T10:32:04+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:27E0390ADABFDF11AB1DF20C369C5409
2010-09-14T10:32:43+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:36F4E256E2C6DF11AAA5A68FD48543AC
2010-09-23T09:15:26+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:BE76034298E1DF1194F6A7BDBDCC45F2
2010-10-27T09:09:23+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:BF76034298E1DF1194F6A7BDBDCC45F2
2010-10-27T09:43:20+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:C076034298E1DF1194F6A7BDBDCC45F2
2010-10-27T09:43:20+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:C176034298E1DF1194F6A7BDBDCC45F2
2010-10-27T09:47:41+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:2385C26927E3DF11A1D7FFCAE040767D
2010-10-29T09:19:09+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:6499BD5F92E5DF1197EEB0EDBA0D5BC0
2010-11-01T10:44:50+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:6A99BD5F92E5DF1197EEB0EDBA0D5BC0
2010-11-01T11:18:43+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:BE8C5D71A7E5DF118CB4CE6078BBF9DE
2010-11-01T13:16:48+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:6105172EB1E8DF11A753B641A055A129
2010-11-05T10:44:52+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:0C428AE8C0E8DF11A753B641A055A129
2010-11-05T11:42:52+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:A73217627AEDDF1191AD98825A3C6EE7
2010-11-11T15:42:21+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:CCC640551AF6DF11BF4EA173CF16F835
2010-11-22T12:14:46+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:EB8A314D94F7DF1194E2943A804C7025
2010-11-24T08:30:16+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:F5EFADB442FDDF11A13A8150ECA8BBCD
2010-12-01T14:01:18+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:F6EFADB442FDDF11A13A8150ECA8BBCD
2010-12-01T14:01:18+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:F7EFADB442FDDF11A13A8150ECA8BBCD
2010-12-01T14:14:53+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:F8EFADB442FDDF11A13A8150ECA8BBCD
2010-12-01T14:57:15+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FAEFADB442FDDF11A13A8150ECA8BBCD
2010-12-01T15:49:52+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:C629F8C7E1FDDF118687865BA3BAC07F
2010-12-02T09:00+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:C729F8C7E1FDDF118687865BA3BAC07F
2010-12-02T09:00+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:C829F8C7E1FDDF118687865BA3BAC07F
2010-12-02T09:20:22+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:B6E1B3880BFEDF118687865BA3BAC07F
2010-12-02T13:58:53+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:F805677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:11:37+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:F905677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:11:37+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:FA05677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:14:19+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FB05677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:49:32+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:FC05677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:49:32+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:FD05677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:53:28+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:FE05677AD6FEDF11B6BEB0C1DC3146AA
2010-12-03T14:54:15+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:7855DA44E3FEDF11B6BEB0C1DC3146AA
2010-12-03T15:59:22+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:7955DA44E3FEDF11B6BEB0C1DC3146AA
2010-12-03T16:00:42+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:03C098EC0501E0118DFD956056236FB5
2010-12-06T08:56:17+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:BDCB8E6CD501E0118139ABDD0BD95C31
2010-12-07T11:48:58+02:00
Adobe InDesign 6.0
/metadata
saved
xmp.iid:BECB8E6CD501E0118139ABDD0BD95C31
2010-12-07T11:48:58+02:00
Adobe InDesign 6.0
/;/metadata
saved
xmp.iid:BFCB8E6CD501E0118139ABDD0BD95C31
2010-12-07T11:54:21+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:C0CB8E6CD501E0118139ABDD0BD95C31
2010-12-07T14:41:54+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:C1CB8E6CD501E0118139ABDD0BD95C31
2010-12-07T15:09+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:C2CB8E6CD501E0118139ABDD0BD95C31
2010-12-07T16:21:05+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:3883D97A8703E011BBCFDCB9638408AB
2010-12-09T13:28:43+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:BEAD12F9F208E0118CD1A1379105AB9F
2010-12-16T11:00:47+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:1FCE8C89A809E011A2A1AC44D3365C34
2010-12-17T08:40:28+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:21CE8C89A809E011A2A1AC44D3365C34
2010-12-17T09:28:52+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:23CE8C89A809E011A2A1AC44D3365C34
2010-12-17T09:39:31+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:8FE4DEFDFA0CE011BC17B9EB9E0EF95D
2010-12-21T15:28:52+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:4FFE2EEB9B1CE011AF50FF63199158A7
2011-01-10T11:30:59+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:06B1C0296E1DE011A620D959CC994409
2011-01-11T12:36:25+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:316CE8211E22E01188C583A954B6B013
2011-01-17T11:42:43+02:00
Adobe InDesign 6.0
/
saved
xmp.iid:366CE8211E22E01188C583A954B6B013
2011-01-17T12:13:57+02:00
Adobe InDesign 6.0
/
ReferenceStream
72.00
72.00
Inches
xmp.iid:8299DD2ED9FEDF11BB41FB6F4669E401
xmp.did:8199DD2ED9FEDF11BB41FB6F4669E401
2011-01-17T12:26:12+02:00
2011-01-17T12:26:13+02:00
2011-01-17T12:26:13+02:00
Adobe InDesign CS4 (6.0)
JPEG
256
256
/9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4AE0Fkb2JlAGSAAAAAAQUAArFD/9sAhAAKBwcHBwcKBwcKDgkJCQ4RDAsLDBEU
EBAQEBAUEQ8RERERDxERFxoaGhcRHyEhISEfKy0tLSsyMjIyMjIyMjIyAQsJCQ4MDh8XFx8rIh0i
KzIrKysrMjIyMjIyMjIyMjIyMjIyMjI+Pj4+PjJAQEBAQEBAQEBAQEBAQEBAQEBAQED/wAARCAEA
ALUDAREAAhEBAxEB/8QBogAAAAcBAQEBAQAAAAAAAAAABAUDAgYBAAcICQoLAQACAgMBAQEBAQAA
AAAAAAABAAIDBAUGBwgJCgsQAAIBAwMCBAIGBwMEAgYCcwECAxEEAAUhEjFBUQYTYSJxgRQykaEH
FbFCI8FS0eEzFmLwJHKC8SVDNFOSorJjc8I1RCeTo7M2F1RkdMPS4ggmgwkKGBmElEVGpLRW01Uo
GvLj88TU5PRldYWVpbXF1eX1ZnaGlqa2xtbm9jdHV2d3h5ent8fX5/c4SFhoeIiYqLjI2Oj4KTlJ
WWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+hEAAgIBAgMFBQQFBgQIAwNtAQACEQMEIRIxQQVRE2Ei
BnGBkTKhsfAUwdHhI0IVUmJy8TMkNEOCFpJTJaJjssIHc9I14kSDF1STCAkKGBkmNkUaJ2R0VTfy
o7PDKCnT4/OElKS0xNTk9GV1hZWltcXV5fVGVmZ2hpamtsbW5vZHV2d3h5ent8fX5/c4SFhoeIiY
qLjI2Oj4OUlZaXmJmam5ydnp+So6SlpqeoqaqrrK2ur6/9oADAMBAAIRAxEAPwCbeU/KflW58q6L
cXGi6fNNNp9rJJJJaws7u0MbMzM0ZJJJ3OKpt/gzyf8A9WHTf+kOD/qnirv8GeT/APqw6b/0hwf9
U8Vd/gzyf/1YdN/6Q4P+qeKu/wAGeT/+rDpv/SHB/wBU8Vd/gzyf/wBWHTf+kOD/AKp4q7/Bnk//
AKsOm/8ASHB/1TxV3+DPJ/8A1YdN/wCkOD/qnirv8GeT/wDqw6b/ANIcH/VPFXf4M8n/APVh03/p
Dg/6p4q7/Bnk/wD6sOm/9IcH/VPFXf4M8n/9WHTf+kOD/qnirv8ABnk//qw6b/0hwf8AVPFXf4M8
n/8AVh03/pDg/wCqeKu/wZ5P/wCrDpv/AEhwf9U8Vd/gzyf/ANWHTf8ApDg/6p4q7/Bnk/8A6sOm
/wDSHB/1TxV3+DPJ/wD1YdN/6Q4P+qeKu/wZ5P8A+rDpv/SHB/1TxV3+DPJ//Vh03/pDg/6p4q7/
AAZ5P/6sOm/9IcH/AFTxV3+DPJ//AFYdN/6Q4P8Aqnirv8GeT/8Aqw6b/wBIcH/VPFXeTP8AlD9B
/wC2bZ/8mI8VTkkL1r9AJ/VirXqL4N/wJ/pjS271F8G/4E/0xpbd6i+Df8Cf6Y0tu9RfBv8AgT/T
Glt3qL4N/wACf6Y0tu9RfBv+BP8ATGlt3qL4N/wJ/pjS2pS3ccL8GDE9dlJGKuiu4pXCKGBPipAx
ViXlbzxqPmG/W3n0xbS3KmswkLHnwMgUKUWuymuZWfTRxxu2nHllI7hlX6Qh/lf/AIE5itzYv4SQ
Ar77fZOKq5cA03+4n+GNK71F8G/4E/0xpbd6i+Df8Cf6Y0tu9RfBv+BP9MaW3eovg3/An+mNLbvU
Xwb/AIE/0xpbd6i+Df8AAn+mNLa7FXYqkvkz/lD9B/7Ztn/yYjxVOsVdirsVdirsVdirsVdirsVd
iqAtND0ixkSazs4oHiBWNkUAqrU5BfCtMnLJKXMsRABH5Bk7FXYq7FXYq7FXYq7FXYq7FXYqkvkz
/lD9B/7Ztn/yYjxVOsVdirE7nQfNElxLJDqXCN3ZkX15hRSSQKBadMVU/wDD3mz/AKun/TxN/wA0
Yq7/AA95s/6un/TxN/zRirv8PebP+rp/08Tf80Yq7/D3mz/q6f8ATxN/zRirv8PebP8Aq6f9PE3/
ADRirv8AD3mz/q6f9PE3/NGKu/w95s/6un/TxN/zRirv8PebP+rp/wBPE3/NGKu/w95s/wCrp/08
Tf8ANGKu/wAPebP+rp/08Tf80Yq7/D3mz/q6f9PE3/NGKu/w95s/6un/AE8Tf80Yq7/D3mz/AKun
/TxN/wA0Yq7/AA95s/6un/TxN/zRirv8PebP+rp/08Tf80YqjdI0fzBaX6T3999YgUMGj9aV6kgg
fC6gdcVZHirsVdiqS+TP+UP0H/tm2f8AyYjxVOsVdirsVdirsVdirsVQ9/BJdWU9vC3pySoyKxqK
EjrtirFP8I65/wAt6/8AByf0xV3+Edc/5b1/4OT+mKu/wjrn/Lev/Byf0xV3+Edc/wCW9f8Ag5P6
YqidN8s6vaX0FzPeLJHE3JkDOaj6RTFWVYq7FXYq7FXYq7FXYq7FXYqkvkz/AJQ/Qf8Atm2f/JiP
FU2nnS2heeSvCMFm4gk0HgBiqWf4m03wm/5Eyf8ANONKmaSq6K6g0YAiu2xxVdzxVwauKoW+1GDT
19S4ZY4xxHJi3VuVB8KN/LhpUD/inSf+WiL75P8AqjjQV3+KdJ/5aIvvk/6o40Fd/inSf+WiL75P
+qONBXf4p0n/AJaIvvk/6o40Fd/inSf+WiL75P8AqjjQV3+KdJ/5aIvvk/6o40Fd/inSf+WiL75P
+qONBXf4p0n/AJaIvvk/6o40Fd/inSf+WiL75P8AqjjQV3+KdJ/5aIvvk/6o40Fd/inSf+WiL75P
+qONBXf4p0n/AJaIvvk/6o40Fd/inSf+WiL75P8AqjjQVVt/MFlduYrWSOWQKz8AXBIUVP2ohjQV
Mo3EsayL0YVGBV+KpL5M/wCUP0H/ALZtn/yYjxVHatT9HXNSFHptUlioG3dlqRirCP3P/LRD/wBJ
Uv8AzRhVN9FutGsQZ7i8T6w1V4iR5FC/7IdcVZFa3dvexetauJY6leQBpUfOmKFdeuBKU+YZfSt2
b12tt4xzSISn/du3EkYeisc+uj/q6z/9IS/814Fd9dH/AFdZ/wDpCX/mvFXfXR/1dZ/+kJf+a8Vd
9dH/AFdZ/wDpCX/mvFXfXR/1dZ/+kJf+a8Vd9dH/AFdZ/wDpCX/mvFXfXR/1dZ/+kJf+a8Vd9dH/
AFdZ/wDpCX/mvFXfXR/1dZ/+kJf+a8Vd9dH/AFdZ/wDpCX/mvFXfXR/1dZ/+kJf+a8Vd9dH/AFdZ
/wDpCX/mvFXfXR/1dZ/+kJf+a8VRuk3IluXT69LcfupP3b2yxD7J35hjhHNDKLL/AHki/wBUYEq+
KpL5M/5Q/Qf+2bZ/8mI8VTO9l9C1ll4iTgpPFmCA07Fm2H04qkP6cf8A6t8H/SXb/wBcKpja3unz
xIZTbwzPsYfUjcg1oBVTQ4oR6qqjioAA7DbFVy9cCUr10zLCxg+s8qx/7xislP3v4YeipB6mo+Gt
f8Cf6YFd6mo+Gtf8Cf6Yq71NR8Na/wCBP9MVd6mo+Gtf8Cf6Yq71NR8Na/4E/wBMVd6mo+Gtf8Cf
6Yq71NR8Na/4E/0xV3qaj4a1/wACf6Yq71NR8Na/4E/0xV3qaj4a1/wJ/pirvU1Hw1r/AIE/0xV3
qaj4a1/wJ/pirvU1Hw1r/gT/AExVGaY9407ib9JcPSkr9bFIvsnrt18MI5qyOy/3ki/1RgVXxVJf
Jn/KH6D/ANs2z/5MR4qmOo8/qU/pgluBoFQSEmnZGIDfLFWH/Vrn/lll/wC4XB/1VwobWC7Rg6W0
qspqCNLgBBHcfvcVT2LWpUiRZdPvpJFUB39BV5MBu3H1Nq4qm8Tc1DUK8gDRtiK9jgSlevoXgYLC
9wax/BHKIT/u3fmQfuw9FY79Xk/6t1z/ANJw/wCaMCu+ryf9W65/6Th/zRirvq8n/Vuuf+k4f80Y
q76vJ/1brn/pOH/NGKu+ryf9W65/6Th/zRirvq8n/Vuuf+k4f80Yq76vJ/1brn/pOH/NGKu+ryf9
W65/6Th/zRirvq8n/Vuuf+k4f80Yq76vJ/1brn/pOH/NGKu+ryf9W65/6Th/zRirvq8n/Vuuf+k4
f80Yq76vJ/1brn/pOH/NGKo3SoXS5dms5oB6UnxyXQlX7J/YCjCOaGTWX+8kX+qMCVfFUl8mf8of
oP8A2zbP/kxHiqZX8LXFnLAoRjIpULJXga/zcSDT5Yqxr/DF1/yzaf8A9PH/AFUwod/hi6/5ZtP/
AOnj/qpiqa6ZodpZencPBEl4vIF4S/Deo2EjH9nFU1XrgSk/mONJbZldIJByiNLmQxJ/u39oOm/0
4VY19Utv+WfTP+k1/wDsoxQ76pbf8s+mf9Jr/wDZRirvqlt/yz6Z/wBJr/8AZRirvqlt/wAs+mf9
Jr/9lGKu+qW3/LPpn/Sa/wD2UYq76pbf8s+mf9Jr/wDZRirvqlt/yz6Z/wBJr/8AZRirvqlt/wAs
+mf9Jr/9lGKu+qW3/LPpn/Sa/wD2UYq76pbf8s+mf9Jr/wDZRirvqlt/yz6Z/wBJr/8AZRirvqlt
/wAs+mf9Jr/9lGKu+qW3/LPpn/Sa/wD2UYqj9Ht4Y7p2SGyQ+lJ8VvctK/2T+wZn/ViOasqsv95I
v9UYEq+KpL5M/wCUP0H/ALZtn/yYjxVMb+OSWzmjiBZ2UhQG4Emn8w6Yqxr9E6t/viT/AKTW/wCa
cKu/ROrf74k/6TW/5pxVOtIsXs4C03qCaX7aPKZgvEtTix8QcUJivXAlKPMRjFuxlaBF5Rb3Ks6V
/e9kBNcPRWNc7P8A39pf/IiX/mjArudn/v7S/wDkRL/zRirudn/v7S/+REv/ADRirudn/v7S/wDk
RL/zRirudn/v7S/+REv/ADRirudn/v7S/wDkRL/zRirudn/v7S/+REv/ADRirudn/v7S/wDkRL/z
Rirudn/v7S/+REv/ADRirudn/v7S/wDkRL/zRirudn/v7S/+REv/ADRirudn/v7S/wDkRL/zRiru
dn/v7S/+REv/ADRiqP0drc3TiOSxZvSk2t4pEf7J7uoGEc0Mpsv95Iv9UYEq+KpL5M/5Q/Qf+2bZ
/wDJiPFUxvxKbOYQ8/U4nj6ZAetP2S21cVSC0k1m2mEslve3CgEenJJFx377Uwqj/wBK6l/1aZv+
Rkf9cUIuyubi5VmuLV7QqaAOyty9/hxVFr1wJSjzFM0NuzrJ6J5RDkYlm/37twYEfThVjX6Ql/5b
R/0gR/8ANOKHfpCX/ltH/SBH/wA04q79IS/8to/6QI/+acVd+kJf+W0f9IEf/NOKu/SEv/LaP+kC
P/mnFXfpCX/ltH/SBH/zTirv0hL/AMto/wCkCP8A5pxV36Ql/wCW0f8ASBH/AM04q79IS/8ALaP+
kCP/AJpxV36Ql/5bR/0gR/8ANOKu/SEv/LaP+kCP/mnFXfpCX/ltH/SBH/zTirv0hL/y2j/pAj/5
pxVHaPdvNdOjXIlBik+H6qkP7J/bVQcRzVlVl/vJF/qjAlXxVJfJn/KH6D/2zbP/AJMR4qmV+0iW
crwlhIqkqUT1Gr7Jty+WKsa+v61/v69/7hw/6qYULo9Q1hXVnkvXQEFl/R4FR3FfUxVMxrikgfUL
4V8bdv64qmq9cCUr1wyiFvRa6Vqx72S85Kfve3JdsPRUi5X/APv3W/8AkR/18wK7lf8A+/db/wCR
H/XzFXcr/wD37rf/ACI/6+Yq7lf/AO/db/5Ef9fMVdyv/wDfut/8iP8Ar5iruV//AL91v/kR/wBf
MVdyv/8Afut/8iP+vmKu5X/+/db/AORH/XzFXcr/AP37rf8AyI/6+Yq7lf8A+/db/wCRH/XzFXcr
/wD37rf/ACI/6+Yq7lf/AO/db/5Ef9fMVdyv/wDfut/8iP8Ar5iqL003Rnf1X1Nl9KTa8i4RfZPU
8238MI5oZFZf7yRf6owJV8VSXyZ/yh+g/wDbNs/+TEeKplf/AFb6nL9cFbfifVG5+Hv9nfFUgtLP
yjezCC2hDyEEgETLsPdqDChHf4Z0P/lkX/gn/wCasVTGCCK1hS3gXhHGKKoqaD6cVVV64EpTr8fq
wMvpyS7xnjDIIm/3bvyYHD0Vj31M/wDLHef9Jkf/ADRgV31M/wDLHef9Jkf/ADRirvqZ/wCWO8/6
TI/+aMVd9TP/ACx3n/SZH/zRirvqZ/5Y7z/pMj/5oxV31M/8sd5/0mR/80Yq76mf+WO8/wCkyP8A
5oxV31M/8sd5/wBJkf8AzRirvqZ/5Y7z/pMj/wCaMVd9TP8Ayx3n/SZH/wA0Yq76mf8AljvP+kyP
/mjFXfUz/wAsd5/0mR/80Yq76mf+WO8/6TI/+aMVRulW5juXY29xF+6k+KW4SVfsn9lVBwjmrJrL
/eSL/VGBVfFUl8mf8ofoP/bNs/8AkxHiqP1XbTrjfj+7b4ufp02/n3p88VYVz/5ef+5h/wA2YVdz
/wCXn/uYf82YqidOultr2GaS5Uopo3O9Ei0IKk8OArSuKswtbiC6jE1vIssZqAymo2wKlvmCITwm
Iwx3JJjYRyyekNvVqQwdOlcKse/Rn/aqtP8ApMb/AKr40h36M/7VVp/0mN/1XxpXfoz/ALVVp/0m
N/1XxpXfoz/tVWn/AEmN/wBV8aV36M/7VVp/0mN/1XxpXfoz/tVWn/SY3/VfGld+jP8AtVWn/SY3
/VfGld+jP+1Vaf8ASY3/AFXxpXfoz/tVWn/SY3/VfGld+jP+1Vaf9Jjf9V8aV36M/wC1Vaf9Jjf9
V8aVGado2myyONSsbe3QCqFLpmJNen98caKUw/w/5V/33H/yPf8A6q40VXxaX5fsfUnshGk3puoI
lZvtClKM5xANqmll/vJF/qjAqviqS+TP+UP0H/tm2f8AyYjxVM71xHayyFPVCqT6ZIHL2+LbFUg/
SsX/AFaU/wCRkH9cKu/SsX/VpT/kZB/XFV8WpW8kqI+mRxqzBWcvAQoJ3Y0PbFU9tvQ4D6vw9Pen
p04/8Liq6SGKWnqoHp0rgVZ9StP99L92Ku+pWn++l+7FXfUrT/fS/dirvqVp/vpfuxV31K0/30v3
Yq76laf76X7sVd9StP8AfS/dirvqVp/vpfuxV31K0/30v3Yq76laf76X7sVd9StP99L92Ku+pWn+
+l+7FXfUrT/fS/dirvqVp/vpfuxVWACgKooB0GKt4qkvkz/lD9B/7Ztn/wAmI8VR+qKX0+4VQWJR
gFCeoTt/J+18sVYX9Tuf+WaX/uHD+uFXfU7n/lml/wC4cP64q76nc/8ALNL/ANw4f1xVl2icPqMa
JA9vwHFlkj9ElqAs4TwJOBUD5hto55oS+rfowhSAlSOe/XaRMVSj6hb/APUz/if+q+Ku+oW//Uz/
AIn/AKr4qmOjyWGmSyST64l4JFChXanGhrXeR8VTb9O6N/y2w/8ABjFXfp3Rv+W2H/gxirv07o3/
AC2w/wDBjFXfp3Rv+W2H/gxirv07o3/LbD/wYxV36d0b/lth/wCDGKu/Tujf8tsP/BjFXfp3Rv8A
lth/4MYq79O6N/y2w/8ABjFXfp3Rv+W2H/gxirv07o3/AC2w/wDBjFUfirsVSXyZ/wAofoP/AGzb
P/kxHiqO1an6NueXGnptXnz49O/pfH92KsH/ANG/5cv+5hhQ7/Rv+XL/ALmGKu/0b/ly/wC5hirM
dCSySxVrEUST4np6lDJQK3H1vip8OBKA8y3EcM8Ae6gtyUNBNbmYnfsfTemKpL9dt/8Aq42X/SCf
+qOKu+u2/wD1cbL/AKQT/wBUcVd9dt/+rjZf9IJ/6o4q767b/wDVxsv+kE/9UcVbN5AACdRswGFR
/oJ3Faf759sVa+u2/wD1cbL/AKQT/wBUcVd9dt/+rjZf9IJ/6o4q767b/wDVxsv+kE/9UcVd9dt/
+rjZf9IJ/wCqOKu+u2//AFcbL/pBP/VHFXfXbf8A6uNl/wBIJ/6o4q767b/9XGy/6QT/ANUcVd9d
t/8Aq42X/SCf+qOKu+u2/wD1cbL/AKQT/wBUcVZ5irsVSXyZ/wAofoP/AGzbP/kxHiqa3MXrQvFz
aPmOPOM8WFe6nscVSv8AQS/9XC//AOkhv6YUIqy08WRci4uLjmAKXEhkAp/LXpiqLxVteuBKR+Yb
h4ZoQs88NVJpDAswO/csRTFUo+vS/wDLZe/9IUf/ADVirvr0v/LZe/8ASFH/AM1Yq769L/y2Xv8A
0hR/81Yq769L/wAtl7/0hR/81Yq769L/AMtl7/0hx/8ANWKu+vS/8tl7/wBIUf8AzVirvr0v/LZe
/wDSFH/zVirvr0v/AC2Xv/SFH/zVirYvZiCReXvwip/0OPxp/N74q19el/5bL3/pCj/5qxV316X/
AJbL3/pCj/5qxV316X/lsvf+kKP/AJqxV316X/lsvf8ApCj/AOasVd9el/5bL3/pCj/5qxVm2Kux
VJfJn/KH6D/2zbP/AJMR4qnDdMVW4UOxV2Ktr1wJSLzHHM88JjS7cBDX6rMsQ6/tBkauKpN6N1/v
rU/+ktP+qWKu9G6/31qf/SWn/VLFXejdf761P/pLT/qlirvRuv8AfWp/9Jaf9UsVd6N1/vrU/wDp
LT/qlirvRuv99an/ANJaf9UsVd6N1/vrU/8ApLT/AKpYq70br/fWp/8ASWn/AFSxVtre6Vivpama
GlRdpQ/8ksVa9G6/31qf/SWn/VLFXejdf761P/pLT/qlirvRuv8AfWp/9Jaf9UsVd6N1/vrU/wDp
LT/qlirvRuv99an/ANJaf9UsVZzirsVSXyZ/yh+g/wDbNs/+TEeKpw3TFVuFDsVdira9cCWO+aY4
HuIDLFayEIaG5meIjf8AZCOlcVSMQWVRW304DufrUv8A1WxVxgsqmlvpxHY/Wpf+q2KtehZ/8s+n
f9JUv/VbFXehZ/8ALPp3/SVL/wBVsVd9Xs/+WbTv+kqX/qtirvQs/wDln07/AKSpf+q2Ku9Cz/5Z
9O/6Spf+q2Ku9Cz/AOWfTv8ApKl/6rYq70LP/ln07/pKl/6rYq70LP8A5Z9O/wCkqX/qtirvQs/+
WfTv+kqX/qtirvQs/wDln07/AKSpf+q2Ku9Cz/5Z9O/6Spf+q2Ku9Cz/AOWfTv8ApKl/6rYq9CxV
2KpL5M/5Q/Qf+2bZ/wDJiPFU4bpiq3Ch2KuxVteuBLHfNM0MVxAJZYIiUNBNbicnfsSjUxVIvrdp
/wAtVl/0gL/1SxV31u0/5arL/pAX/qlirvrdp/y1WX/SAv8A1SxV31u0/wCWqy/6QF/6pYqvfUIZ
AiyXto4jHFA1iCFXrRax7DFVn1u0/wCWqy/6QF/6pYqqR3em8X9a6teVP3fCwSnL/KrF0xVT+t2n
/LVZf9IC/wDVLFXfW7T/AJarL/pAX/qlirvrdp/y1WX/AEgL/wBUsVd9btP+Wqy/6QF/6pYq763a
f8tVl/0gL/1SxV31u0/5arL/AKQF/wCqWKtrc2zsES4s2ZjRVFgCST0A/dYq9BxV2KpL5M/5Q/Qf
+2bZ/wDJiPFU4bpiq3Ch2KuxVteuBKB1PU7mxdEgs2uw4JLK4Wm/TcYqgv8AEOof9WmT/kav9MVd
/iHUP+rTJ/yNX+mKu/xDqH/Vpk/5Gr/TFXf4h1D/AKtMn/I1f6Yq7/EOof8AVpk/5Gr/AExV3+Id
Q/6tMn/I1f6Yq7/EOof9WmT/AJGr/TFXf4h1D/q0yf8AI1f6Yq7/ABDqH/Vpk/5Gr/TFXf4h1D/q
0yf8jV/pirv8Q6h/1aZP+Rq/0xV3+IdQ/wCrTJ/yNX+mKu/xDqH/AFaZP+Rq/wBMVd/iHUP+rTJ/
yNX+mKp9irsVSXyZ/wAofoP/AGzbP/kxHiqcN0xVbhQ7FXYq2vXAljvmmOB7iAyxWshCGhuZniI3
/ZCOlcVSL0LP/ln07/pKl/6rYq70LP8A5Z9O/wCkqX/qtirvQs/+WfTv+kqX/qtirvQs/wDln07/
AKSpf+q2Ku9Cz/5Z9O/6Spf+q2Ku9Cz/AOWfTv8ApKl/6rYq70LP/ln07/pKl/6rYq70LP8A5Z9O
/wCkqX/qtirvQs/+WfTv+kqX/qtirvQs/wDln07/AKSpf+q2Ku9Cz/5Z9O/6Spf+q2Ku9Cz/AOWf
Tv8ApKl/6rYq70LP/ln07/pKl/6rYq70LP8A5Z9O/wCkqX/qtir0LFXYqkvkz/lD9B/7Ztn/AMmI
8VThumKrcKHYq7FW164Esd80zQxXEAllgiJQ0E1uJyd+xKNTFUi+t2n/AC1WX/SAv/VLFXfW7T/l
qsv+kBf+qWKu+t2n/LVZf9IC/wDVLFXfW7T/AJarL/pAX/qlirvrdp/y1WX/AEgL/wBUsVd9btP+
Wqy/6QF/6pYq763af8tVl/0gL/1SxV31u0/5arL/AKQF/wCqWKu+t2n/AC1WX/SAv/VLFXfW7T/l
qsv+kBf+qWKu+t2n/LVZf9IC/wDVLFWzeWpABu7MhRQf6CNh1/3174q5buy5DldWfGu9LBa0/wCR
WKuN3Z1NLqzp2/0Bf+qWKvQcVdiqS+TP+UP0H/tm2f8AyYjxVOG6YqtwodirsVbXrgSl+qWhuJI2
GoyWHEEcUYLy367kYqgf0Y3/AFf5v+Ri/wDNWKu/Rjf9X+b/AJGL/wA1Yq79GN/1f5v+Ri/81Yq7
9GN/1f5v+Ri/81Yq79GN/wBX+b/kYv8AzVirv0Y3/V/m/wCRi/8ANWKu/Rjf9X+b/kYv/NWKu/Rj
f9X+b/kYv/NWKu/Rjf8AV/m/5GL/AM1Yq79GN/1f5v8AkYv/ADVirv0Y3/V/m/5GL/zViqZ2TW1p
AInvfrDVqZJZASTQDx2G2Koj65af7/j/AODX+uKu+uWn+/4/+DX+uKq2KuxVJfJn/KH6D/2zbP8A
5MR4qnDdMVW4UOxV2Ktr1wJSDzKkDTweqlmx4Gn1uR0br+zwI2xVJfRs/wDfWlf8j5f+asVd6Nn/
AL60r/kfL/zVirvRs/8AfWlf8j5f+asVd6Nn/vrSv+R8v/NWKu9Gz/31pX/I+X/mrFXejZf760r/
AJHy/wDNeKu9Gz/31pX/ACPl/wCasVd6Nn/vrSv+R8v/ADVirvRs/wDfWlf8j5f+asVd6Nn/AL60
r/kfL/zVirvRs/8AfWlf8j5f+asVd6Nn/vrSv+R8v/NWKu9Gz/31pX/I+X/mrFXejZ/760r/AJHy
/wDNWKs8xV2KpL5M/wCUP0H/ALZtn/yYjxVMb+SSGzmli/vEUlfhL7gfyjc4qxr9N6z4/wDTpL/X
Crv03rPj/wBOkv8AXFUXpmsXslyIr1XZZKKnC3kSjEjdmYnbFWQL1wKx7zPPDFPAJJLSMlDQXUDT
E7/slY3piqSfXLX/AH/pn/SE/wD1QxV31y1/3/pn/SE//VDFXfXLX/f+mf8ASE//AFQxV31y1/3/
AKZ/0hP/ANUMVd9ctf8Af+mf9IT/APVDFV/rwf8ALRpX/SKf+qOKrPrlr/v/AEz/AKQn/wCqGKu+
uWv+/wDTP+kJ/wDqhirvrlr/AL/0z/pCf/qhirvrlr/v/TP+kJ/+qGKu+uWv+/8ATP8ApCf/AKoY
q765a/7/ANM/6Qn/AOqGKu+uWv8Av/TP+kJ/+qGKu+uWv+/9M/6Qn/6oYqz/ABV2KpL5M/5Q/Qf+
2bZ/8mI8VR2qlV064LUCiNq1JUdO5TcfRirCPrFp/PD/ANJFz/zThV31i0/nh/6SLn/mnFWSeW4K
QvdgLwmoI2SWSQEKWB/vaU3xVPF64FSPzDLJHNCEupbYFTUR24nB36kkimKpR9auP+rnc/8ASAP+
asVd9auP+rnc/wDSAP8AmrFXfWrj/q53P/SAP+asVd9auP8Aq53P/SAP+asVd9ZuP+rncf8ASAP+
asVd9ZuP+rncf9IA/wCasVd9auP+rnc/9IA/5qxV31q4/wCrnc/9IA/5qxV31q4/6udz/wBIA/5q
xV31q4/6udz/ANIA/wCasVd9auP+rnc/9IA/5qxV31q4/wCrnc/9IA/5qxV31q4/6udz/wBIA/5q
xV31q4/6udz/ANIA/wCasVZtirsVSXyZ/wAofoP/AGzbP/kxHiqa3MP1iB4CzRiQFeSGjCvcGhxV
Kv8ADUf/AC33n/Ixf+qeKu/w1H/y33n/ACMX/qniqPsrH6lD6ImknFS3KYhmFe2wXbFUSFocVQOo
6dcXro8N7NaBAQViNA3ucVQn6Avf+rxd/f8A24q79AXv/V4u/v8A7cVd+gL3/q8Xf3/24q79AXv/
AFeLv7/7cVd+gL3/AKvF39/9uKu/QF7/ANXi7+/+3FXfoC9/6vF39/8Abirv0Be/9Xi7+/8AtxV3
6Avf+rxd/f8A24q79AXv/V4u/v8A7cVd+gL3/q8Xf3/24q79AXv/AFeLv7/7cVd+gL3/AKu919/9
uKu/QF7/ANXi7+/+3FU7xV2KpL5M/wCUP0H/ALZtn/yYjxVOTy/ZAPzNP4HFWqyfyr95/wCacVdW
T+VfvP8AzTirqyfyr95/5pxV1ZP5V+8/804q6sn8q/ef+acVdV6EkCvYA9fwGKqHr3X/ACzH/g1x
V3r3X/LMf+DXFV8cs7OBJAY1/m5KfwGKvOfI3mvzjq+vJZ60H+qGKRjytxEOSj4fiCLmdqcGKELj
zcTBlySlReh+vdf8sx/4NcwXLd691/yzH/g1xV3r3X/LMf8Ag1xVWVpGQEoFY9VJ6fSAcVbrJ/Kv
3n/mnFXVk/lX7z/zTirqyfyr95/5pxV1ZP5V+8/804q6sn8q/ef+acVXYq7FWH+U/NnlW28q6Lb3
GtafDNDp9rHJHJdQq6OsMasrK0gIII3GKpt/jPyf/wBX7Tf+kyD/AKqYq7/Gfk//AKv2m/8ASZB/
1UxV3+M/J/8A1ftN/wCkyD/qpirv8Z+T/wDq/ab/ANJkH/VTFXf4z8n/APV+03/pMg/6qYq7/Gfk
/wD6v2m/9JkH/VTFXf4z8n/9X7Tf+kyD/qpirv8AGfk//q/ab/0mQf8AVTFXf4z8n/8AV+03/pMg
/wCqmKu/xn5P/wCr9pv/AEmQf9VMVd/jPyf/ANX7Tf8ApMg/6qYq7/Gfk/8A6v2m/wDSZB/1UxV3
+M/J/wD1ftN/6TIP+qmKu/xn5P8A+r9pv/SZB/1UxV3+M/J//V+03/pMg/6qYq7/ABn5P/6v2m/9
JkH/AFUxV3+M/J//AFftN/6TIP8Aqpirv8Z+T/8Aq/ab/wBJkH/VTFXf4z8n/wDV+03/AKTIP+qm
Ku/xn5P/AOr9pv8A0mQf9VMVd/jPyf8A9X7Tf+kyD/qpirv8Z+T/APq/ab/0mQf9VMVf/9k=
6113
xml
Adobe PDF Library 9.0
False
The endothelin system in breast tumour–endothelial
cell interactions
Authors:
Tasnim Badat1
Julia Botha1
Strinivasen Naidoo1
Affiliation:
1Department of Therapeutics and Medicines Management, University of KwaZulu-Natal, South Africa
Correspondence to:
Strinivasen Naidoo
email:
naidoot@ukzn.ac.za
Postal address:
Private Bag X7, Congella 4013, South Africa
Dates:
Received: 23 Apr. 2010
Accepted: 22 Nov. 2010
Published: [To be released]
How to cite this article:
Badat T, Botha J, Naidoo S. The endothelin system in breast tumour–endothelial cell interactions. S Afr J Sci. 2011;107(1/2), Art. #233,
5 pages. DOI: 10.4102/sajs.v107i1/2.233
© 2011. The Authors.
Licensee: OpenJournals
Publishing. This work
is licensed under the
Creative Commons
Attribution License.
The role of endothelin-1 (ET-1) and its receptors (ET-RA and ET-RB) in tumour development and progression involves complex interactions. ET-1, produced by tumours and associated cells like endothelial cells, functions in an autocrine and paracrine manner to promote tumour angiogenesis. Thus, we hypothesised that endothelin, released into the tumour milieu by both tumours and the tumour vasculature, would influence angiogenesis. Therefore, this preliminary study aimed to investigate changes in ET1, ET-RA and ET-RB in breast tumour and microvascular endothelial cultures when each cell type was exposed directly to the other (co-culture model) as well as to the conditioned-medium metabolites of the other (challenge model). ET-1 secretion was measured by an enzyme-linked immunosorbent assay and
ET-1, ET-RA and ET-RB expression investigated by the linked streptavidin–biotin method. In challenge experiments, endothelial metabolites significantly increased secretion of breast tumour ET-1. Tumour metabolites promoted endothelial membrane projections with no effect on ET-1 secretion. ET-1 and its receptors were immunolocalised in both cell types, including in projections. Increasing cancer cell conditioned medium resulted in decreased endothelial ET-RA and increased ET-RB staining. Co-cultures demonstrated ET proteins in projections of both cell types as well as at heterogeneous contact points. The findings support a role for the endothelin system in endothelial cell and breast cancer cell invasion. It is tempting to consider that early endothelial and tumour cell alterations may be promoted by ET-1 produced by both cell types. Further work is required that will examine localised cellular gene expression of the endothelin system as well as its pro-invasive and angiogenic effects in breast cancer models.
Introduction
Endothelin-1 (ET-1), together with its cognate receptors endothelin receptor subtype A
(ET-RA) and endothelin receptor subtype B (ET-RB), is known to be one of the many mediators that play a role in angiogenesis.1 For example, it has been shown that ET-1, acting via ET-RB and in concert with vascular endothelial growth factor (VEGF), promotes proliferation, migration and invasion of umbilical vein endothelial cells (HUVECs).2 The ET axis has also been found to be over-expressed by cancer cells and there is evidence that it is involved, in association with VEGF and other factors, in tumour angiogenesis.3 For example, in ovarian cancer, ET-1 stimulates early neovascularisation (proliferation and migration of endothelial cells) via ET-RB receptors.4 The ET system also plays a less direct role in angiogenesis by, for example, breaking down the extracellular matrix.3,5 Studies have linked increased tumour vascularity to ET-1 in brain tumours, ovarian and colorectal cancer,4,6,7 and in a series of 600 core biopsies from 200 breast cancer specimens, ET-1, ET-RA, ET-RB and VEGF correlated with microvascular density.8
While tumour angiogenesis is pivotal to tumour growth and metastasis, the ET system also has other functions in tumour cells. Among these are mitogenic effects (often mediated via
ET-RA), resistance to apoptosis, and promotion of migration and invasion. There is considerable variability between tumour types and even from one individual to another.5 In breast cancer, investigators have shown that ET-1 and its receptors correlate with malignant potential,9 while other work has highlighted the role of ET in tumour cell invasion and has explored the influence of the tumour’s micro-environment on the ET system and its resultant effects.10
The overall contribution of the ET system to tumour angiogenesis, as well as to tumour spread and development, is a result of complex interactions as ET is both produced by, and influences the vasculature and the tumour cells. Therefore, we set up a preliminary study to further explore the inter-relationship between the ET system, endothelial cells and breast tumour cells using two models that mimic the complicated in vivo micro-environment. We investigated the endothelin system when two cell types, namely human dermal microvascular endothelial cells (DMVEC) and the human breast tumour cell line (MCF-7) were cultured together and when each was exposed to the metabolites/conditioned medium (CM) of the other. The aim in this pilot phase was to determine the induction of the endothelin system in heterogeneous cell culture models by measuring protein synthesis, sequestration and the subsequent effects following release.
Materials and methods
Ethical approval
The project was approved by the Biomedical Research Ethics Committee, University of KwaZulu-Natal (Reference H074/06).
Cell culture
Human dermal microvascular endothelial cells (DMVECs) were purchased from Cambrex BioScience (New Jersey, USA) and MCF-7 cells were obtained from Highveld Biological, National Repository for Biological Material of the Cancer Association of South Africa (Johannesburg, South Africa). The DMVECs were maintained in supplier-specified endothelial growth medium (EGM®-2 MV; Cambrex BioScience) and the
MCF-7 cells in supplemented Eagles Minimum Essential Medium (EMEM; Cambrex BioScience), both with 10% foetal calf serum at 37 °C/5% CO2. Tumour medium was supplemented further as previously described.11 Only DMVECs between passages 4 and 12 were used for the challenge and co-culture models.
Challenge model
The challenge model was performed according to a previous method.11 Briefly, seeding densities of DMVECs and
MCF-7 were 3 x 103 cells/cm2 and 3.5 x 103 cells/cm2, respectively. At approximately 60% confluency, CM was extracted from each line and added to the other cell line at concentrations of 10%, 25% and 50%. Thus metabolites were presented to proliferating cell lines in a dose-controlled manner. Following 24-h incubation, cell proliferation was measured by a formazan-reduction assay (MTT) and the spent media collected for ET-1 measurement by an enzyme-linked immunosorbent assay (ELISA). In an identical experiment, after challenging the cells, they were serum-cleared overnight at 37 °C/5% CO2, fixed in ice-cold methanol for 20 min at -20 °C and then immunostained for ET-1, ET-RA and ET-RB.
Co-culture model
The co-culture model has been previously described.11 Briefly, DMVECs were seeded onto 8-chamber glass slides (Iwaki Glass Co., Iwaki, Japan) at
2 x 103 cells/cm2. After 24 h, MCF-7 cells were added to each DMVEC chamber at 2 x 103 cells/cm2. Thereafter, the heterogeneous endothelial–tumour cell populations were left to interact for approximately 24 h at 37 °C/5% CO2. Once cell interaction had been established with an inverted microscope (DMIL, Leica, Wetzlar, Germany), co-culture sets were serum-cleared and fixed as described for the challenge model above, and then immunostained for ET-1, ET-RA and ET-RB.
Cell projections
Projections are membrane extensions emanating from the cell periphery, and, in the present context, were considered to be a function of cellular motility. To determine whether tumour CM influenced the number of membrane projections produced by the DMVECs, these projections were counted. In each field of view, archived as a 24-bit TIFF image, the number of visible projections was counted by two independent observers. Two fields of view for each of the four challenge ratios were evaluated.
ET-1 secretion
ET-1 concentration was measured using a commercial human ET-1 sandwich ELISA kit (Assay Designs, Ann Arbor, USA), as per supplier’s instructions. The sensitivity range of the assay was between 0.14 pg/mL and
100 pg/mL. Controls consisted of assay buffer (blanks) and internal controls (fresh media). Two independent experiments were performed with duplicate standards and quadruplicate samples for each challenge ratio.
ET-1, ET-RA and ET-RB expression
The linked streptavidin-biotin (LSAB) method11 was used to immunolabel the control tissues and cultured cells for
ET-1, ET-RA and ET-RB. Normal placental tissue was used for ET-1 and normal kidney tissue was used for both ET-RA and
ET-RB detection. Briefly, fixed DMVEC and MCF-7 cells were processed and incubated with their respective polyclonal rabbit anti-human ET-1, ET-RA and ET-RB IgG at the following dilutions, respectively: (1) DMVECs at 1:150, 1:100 and 1:200; MCF-7 at 1:350, 1:100 and 1:300 and (2) tissues at 1:300, 1:300, 1:1000. Following this, as per manufacturer’s instructions, an avidin-biotin kit (LSAB-2, Dako, Ely, UK) and substrate 3,3’-diaminobenzidine (DAB; Dako) was used to visualise staining. As a positive cell culture control, unchallenged DMVECs were also immunolabelled for the endothelial cell-specific protein, von Willebrand Factor (1:200, vWF; Dako). For the negative controls, for both tissues and cells, the primary antibody was substituted with milk blocker solution.
For the co-cultures, the fixed heterogeneous cell populations (DMVEC:MCF-7) on the chamber slides were first immunostained for ET-1, ET-RA and ET-RB using the LSAB-DAB method above. Thereafter, to be able to distinguish between the DMVECs and the tumour cells in the same micro-environment, the DMVECs were labelled for vWF using the fast red-alkaline phosphatase method described previously.11
Image analysis in the challenge model
The immunolabelled control tissues as well as the
challenged and co-cultured cells were viewed under a
bright-field, phase contrast microscope (DMLB; Leica) coupled to a digital camera (DFC 300FX; Leica) and results were captured as TIFF images and archived. For each challenge group, the AnalySIS Pro™ 5 software12 was used to analyse cells
(n = 8) for staining intensity (that is, concentration of protein). To quantify the immunostaining, the archived 24-bit TIFF images were converted to 8-bit binary images with a grey scale of 256 phases and for each region of interest the mean grey scale intensity value and the area were calculated. Non-specific background, calculated from immunostaining in method controls, was considered to be less than 120 pixels/µm2.
Statistical analysis
All challenge and co-culture experiments were repeated. Statistical significance (p ≤ 0.05) was tested with Kruskal-Wallis followed by Dunn’s multiple comparisons post-hoc test for both the ELISA and image analysis data. All statistical analyses were performed using GraphPad Instat.13
Results
Challenge model: DMVECs challenged with MCF-7 CM
Immunoreactive ET-1, ET-RA and ET-RB were all found in the peri-nuclear and cytoplasmic regions of DMVECs and were particularly marked in cell projections (Figure 1a, 1c and 1e). Further, on visual (qualitative) examination, there appeared to be no change in the intensity of immunostaining of any of these three target proteins with increasing concentrations of CM. However, when quantified using image-analysis software, there was a small but significant decrease in the intensity of ET-RA staining (p = 0.05), while, in contrast, the intensity of staining of ET-RB increased by a maximum of 36% (0% to 25% CM, p < 0.01 and 10% to 25% CM, p < 0.01) (graphs not shown). There were no significant changes in the intensity of ET-1 staining in DMVECs as the concentration of MCF-7 CM increased. Further, no appreciable change in secretion of ET-1 was detected in response to increasing concentrations of CM (not shown). The baseline concentration of ET-1 secreted from DMVECs was 92.3 pg/mL ± 1.5 pg/mL (not shown). The number of membrane projections on DMVECs, per field of view, increased with increasing concentrations of MCF-7 CM and, on average, there were increases of 76% and 46% at 10% and 50% challenge ratios, respectively, when compared to baseline.
Challenge model: MCF-7 challenged with DMVEC CM
Although mean baseline secretion of ET-1 from the MCF-7 cells was only 11.6 pg/mL ± 0.2 pg/mL, ET-1 secretion, in response to increasing concentrations of DMVEC CM (p < 0.01), increased significantly with an approximate 11-fold increase at the 50% challenge (112 pg/mL ± 3.3 pg/mL)
(Figure 2). While ET-1, ET-RA and ET-RB were found in the MCF-7 cells (Figures 1b, 1d and 1f), especially in projections (not shown), there were no appreciable changes in the intensity of staining (quantitative) with increasing concentrations of DMVEC CM (graphs not shown).
Co-culture model
When co-cultured, both DMVECs and tumour cells demonstrated ET-1, ET-RA and ET-RB staining, especially at heterogeneous points of contact and in tumour cell projections (Figures 1g and 1h).
Discussion
Immunolabelling showed that ET-1, ET-RA and ET-RB were expressed in both cultured DMVECs and MCF-7 cells. Components of the ET system have previously been reported in endothelial cells including those lining tumour-feeding vessels in ovarian carcinomas.4 In our study, ET-1 and its receptors were found in DMVEC projections. In the co-culture model (which allowed not only exposure of each cell line to the metabolites of the other but also direct cell to cell contact), projections from tumour cells and DMVECs were observed extending towards each other.
Because ET-1 and its receptors were co-localised in projections of both cell types, ET-1 may have played a chemotactic role in promoting these effects, which are consistent with early cell invasion and migration. A role for ET in migration and invasion of endothelial cells in tumour angiogenesis has been previously proposed3,5 and we found that increasing concentrations of MCF-7 metabolites caused a marked increase in the number of projections on DMVECs. This finding is consistent with previous work that showed that CM from an ovarian carcinoma cell line increased endothelial cell migration.4 Those authors also found that the angiogenic response was reduced by 76% if the CM was co-incubated with VEGF antibody and an ET-RB antagonist, indicating that VEGF and ET-RB receptors were important in migration. In our experiments with MCF-7 CM, there was increased intensity of staining of ET-RB receptors in DMVECs as the concentration of tumour metabolites increased up to 25%.
ET is considered to play a role in endothelial cell proliferation, and increased proliferation has been reported upon exposure to CM from human breast cancer cells.3,14 While we have also previously shown that MCF-7 CM increases DMVEC proliferation,11 the present study found that MCF-7 CM did not induce DMVECs to secrete more ET-1 into the surrounding medium, nor did it cause a significant change in intensity of immunostaining of ET-1 in DMVECs. Thus it appears that any changes observed in DMVECs, as a result of MCF-7 CM, were not brought about by changes in endothelial cell ET-1. However, it is now recognised that there is a complex interaction between ET-1, tumour cells and other associated cells, such that various cell types not only both produce and are affected by ET, but also influence one another’s production of ET.15 Co-culture of tumour cells with macrophages, for example, leads to increased ET production.15 Of particular interest in our study was the finding that ET-1 production by MCF-7 increased progressively and significantly when these cells were exposed to increasing amounts of DMVEC metabolites. Considering the interplay between different cell types in the tumour environment, and the autocrine and paracrine effects of ET-1, we postulate that DMVECs promote MCF-7 to produce more ET-1, which may then play a paracrine role on the endothelial cells.
The ET-1 produced by MCF-7 could also be expected to have an autocrine function. The presence of ET-1 and its receptors in MCF-7 projections and at points of contact between endothelial and tumour cells in our study are consistent with the previously proposed role for ET in tumour invasion.3,5,15 Our concentrations of
11.6 pg/mL ± 0.2 pg/mL ET-1 produced by MCF-7 after 24-h incubation are comparable with previous findings where cultured MCF-7 cells, a moderately invasive cell line, produced less than 4 pg/mL after a similar incubation period.16 Hagemann et al.16 found that the amount of ET-1 produced by different breast tumours correlated with their invasiveness. They also showed that endothelins promote invasion of MCF-7 cells and that the effect could be inhibited by either ET-RA or ET-RB receptor antagonists. It has been proposed that endothelins produced by endothelial cells may encourage tumour cell extravasation.10 Our finding that CM from DMVEC caused MCF-7 to increase their output of ET-1 further supports the hypothesis that ET-1 is involved in functional interactions between tumour cells and their vasculature. The high baseline concentrations of ET-1 secreted from the DMVECs may have been sufficient to stimulate the increased secretion of ET-l from the cancer cells as previously demonstrated in HUVECs, where ET-1 can stimulate its own synthesis.17
Conclusion
The results of our study are consistent with a role for ET-1 and its receptors in breast tumour and endothelial cell invasion. The findings lend support to both autocrine and paracrine roles for ET-1 and to the complex interactions which exist in the micro-environment in which vascular and tumour cells co-exist in such close proximity. Further development of this preliminary study will incorporate cellular gene expression by in situ real-time polymerase chain reaction, as well as chemotaxis and invasion assays.
Acknowledgements
We thank the University of KwaZulu-Natal and the South African National Research Foundation for funding part(s) of this project.
References
1. Cruz A. Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. J Vasc Res. 2001;38:536–545.
2. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo. Am J Pathol. 2000;157:1703–1711.
3. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004;2(1):16.
4. Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000;157:1537–1547.
5. Knowles J, Lozidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol. 2005;3(4):309–314.
6. Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor [beta]1 with malignancy and vascularity in human gliomas. J Neuropathol Exper Neurol. 1997;56(4):435–439.
7. Shankar A, Loizidou M, Aliev G, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg. 1998;85(4):502–506.
8. Wülfing P, Kersting C, Tio J, et al. Characterization of expression of the endothelin-axis in breast cancer tissues and human breast cancer cell lines. Proc Am Assoc Cancer Res. 2004;45:708–709.
9. Wülfing P, Diallo R, Kersting C, et al. Endothelin-1, endothelin-A- and endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncol Rep. 2004;11:791–796.
10. Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett. 2005;222(2):129–138.
11. Wright JK, Botha JH, Naidoo S. Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. Tumor Biol. 2008;29:130–136.
12. Olympus Soft Imaging Solutions GmbH. AnalySIS Pro. 5 ed. Munster; 1986–2006.
13. GraphPad Software. Instat. 3.10 ed. La Jolla; 1995–2009.
14. Wellstein A. Growth factor targeted and conventional therapy of breast cancer. Breast Cancer Res Treat. 1994;31:141–152.
15. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumour cell invasion. Cancer Res. 2004;64:2461–2468.
16. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol. 2005;24(11):766–776.
17. Saijonmaa O, Nyman T, Fyhrquist F. Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem Biophys Res Comm. 1992;188(1):286–291.
a
b
c
d
e
f
g
h
400x magnification
(a-f): Labelling in the cell bodies (shown by black arrows) and cell membrane projections (shown by blue arrows) is depicted as brown substrate 3,3’-diaminobenzidine stain. (g and h): DMVECs are designated ‘ec’ and were identified by co-labelling with von Willebrand Factor, depicted as red stain.
FIGURE 1: Immunostaining of the endothelin system in breast tumour–endothelial cell challenge and co-culture models. Immunoreactive endothelin-1 in unchallenged, control human dermal microvascular endothelial cells (DMVECs) (a) and human breast tumour cells (MCF-7) (b). Negative controls (c and d insets) demonstrated no staining in both control DMVECs and MCF-7. ET-RA in challenged DMVECs (c) and MCF-7 (d). ET-RB in DMVECs (e) and MCF-7 (f). ET-RA (g) and ET-RB (h) in DMVEC–MCF-7 co-cultures at the points of contact between the two cell types (shown by black arrows).
Data presented as mean ± SEM (n = 8).
*p < 0.05 vs. control (0% dose).
FIGURE 2: Secretion of endothelin-1 (ET-1) by human breast tumour cells (MCF-7) challenged by human dermal microvascular endothelial cell (DMVEC) metabolites. The concentration of ET-1 secreted from MCF-7 cells, measured by commercial sandwich ELISA, shows a dose-dependent, significant increase in response to DMVEC conditioned medium/metabolites.